Safety and efficacy of varicella zoster immune globulin (human) VariZIG in patients at-risk of varicella infection.

Trial Profile

Safety and efficacy of varicella zoster immune globulin (human) VariZIG in patients at-risk of varicella infection.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Apr 2013

At a glance

  • Drugs Varicella zoster immune globulin (Primary)
  • Indications Chickenpox; Herpes zoster
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Dec 2008 Planned end date changed from 1 Jul 2007 to 1 Dec 2009 as reported by ClinicalTrials.gov.
    • 08 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top